Beauty Can Benefit From FDA Guidance On Third-Party Misinformation Online
This article was originally published in The Rose Sheet
Executive Summary
While targeted to drug and medical-device manufacturers, FDA’s draft guidance spells out the agency’s expectations for firms in terms of what third-party messaging they are responsible for, and how corrections to erroneous user-generated content should be undertaken in the online environment.